Reply: Beneficial effect of interleukin-2-based immunomodulation in Alzheimer-like pathology

Sandro Alves; Guillaume Churlaud; David Klatzmann; Nathalie Cartier

doi:10.1093/brain/awx109

Journal Articles Brain - A Journal of Neurology Year : 2017

Reply: Beneficial effect of interleukin-2-based immunomodulation in Alzheimer-like pathology

(1) , (2) , (3) , (1)

1
2
3

Sandro Alves

Function : Author

Thérapie génique, Génomique et Epigénomique

Guillaume Churlaud

Function : Author

Departement Hospitalo- Universitaire - Inflammation, Immunopathologie, Biothérapie [Paris]

David Klatzmann

Function : Author
PersonId : 860339

Service de biothérapies [CHU Pitié-Salpétrière]

Nathalie Cartier

Function : Author

Thérapie génique, Génomique et Epigénomique

Abstract

No abstract available

Domains

Life Sciences [q-bio] Human health and pathology

Embargoed file

Ne sera jamais visible

DAVID KLATZMANN : Connect in order to contact the contributor

https://www.hal.inserm.fr/inserm-01617417

Submitted on : Tuesday, November 15, 2022-3:37:03 PM

Last modification on : Thursday, November 24, 2022-3:09:05 AM

Dates and versions

inserm-01617417 , version 1 (15-11-2022)

Identifiers

HAL Id : inserm-01617417 , version 1
DOI : 10.1093/brain/awx109
PUBMED : 28498902

Cite

Sandro Alves, Guillaume Churlaud, David Klatzmann, Nathalie Cartier. Reply: Beneficial effect of interleukin-2-based immunomodulation in Alzheimer-like pathology. Brain - A Journal of Neurology , 2017, 140 (7), pp.e40 - e40. ⟨10.1093/brain/awx109⟩. ⟨inserm-01617417⟩

Export

BibTeX TEI Dublin Core DC Terms EndNote Datacite

Collections

INSERM CEA UPMC CNRS CEA-UPSAY UNIV-PARIS-SACLAY SORBONNE-UNIVERSITE SU-MEDECINE

42 View

0 Download

Reply: Beneficial effect of interleukin-2-based immunomodulation in Alzheimer-like pathology

Abstract

Domains

Dates and versions

Identifiers

Cite

Export

Collections

Altmetric

Share